ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design
21.10.2025 17:30:00 EEST | Business Wire | Press release
Today ChipAgents, the agentic AI platform transforming chip design and verification, announced the close of a $21 million Series A funding round, bringing the total fundraise to $24 million to date. This latest round closed with Bessemer Venture Partners, with strategic backing from Micron, MediaTek, Ericsson, and additional top semiconductor companies. Also participating in the round are notable angels including new advisors, Wally Rhines, Raúl Camposano,and Jack Harding, and existing support by ScOp Venture Capital (Ivan Bercovich) and Amino Capital, fueling the company’s expansion of product development, customer acquisition, and strategic industry partnerships.
ChipAgents’ mission is to bring the power of AI to the heart of chip design and verification. Every engineer should be empowered with tools that make the most complex aspects of hardware development faster, more intuitive, and dramatically more productive. Chips are the foundation of our digital world, yet the process of building and verifying them remains slow, costly, and labor-intensive. By rethinking workflows with AI, ChipAgents shortens design cycles, accelerates innovation, and helps semiconductor companies deliver breakthroughs that will shape the next decade of technology.
“Electronic design automation (EDA) has powered decades of semiconductor progress, but today’s engineers still struggle with fragmented toolchains, steep costs, and workflows that haven’t kept pace with rapidly growing chip complexity,” said Founder and CEO, Professor William Wang. “As designs scale, productivity gains have slowed and verification remains highly manual. Our vision is to change that. With ChipAgents, we’re introducing a unified agentic AI platform designed to automate routine tasks, accelerate design and verification, and enable AI-native workflows that help engineers focus on innovation rather than repetitive effort.”
Building on the momentum of its seed round, ChipAgents saw a 6,377% surge in monthly usage in the first half of 2025, leveraging agentic AI to accelerate RTL code generation, testbench creation, debugging, and verification through intuitive, language-based commands. The result: expedited time-to-market, cost reductions, and a redefined benchmark for productivity in chip development. Across independent teams, ChipAgents achieves 80% higher productivity in verification compared to industry practices and is deployed at 50 leading semiconductor companies, showcasing its ability to deliver real-world value at scale. The company sees a 50x YoY growth in annual recurring revenue (ARR) in the beginning of its second year.
"ChipAgents has demonstrated itself as having the best product in the market that does AI-powered RTL design, debugging, and verification for chip developers,” said Lance Co Ting Keh, Venture Partner at Bessemer Venture Partners. “We’re impressed by Professor William Wang’s deep technical expertise and the exceptional team of AI and hardware design experts he’s assembled. ChipAgents’ agentic approach to AI chip design integrates seamlessly across the entire chip design workflow, bringing together disparate EDA tools from spec ingestion to waveform analysis, which we believe is the right way to tackle this complex, multi-step process. The feedback from customers and technical experts validates that ChipAgents isn't just automating individual tasks, but creating a true force multiplier for hardware design engineers.”
“Micron Ventures supports bold AI companies led by visionary founders developing transformative technologies. ChipAgents’ mission to reinvent chip design through AI agents aligns closely with our focus, especially as chipmakers require faster, more intelligent design solutions to meet the accelerating demands of AI hardware. At this pivotal inflection point, ChipAgents presents a high-impact opportunity to invest in the future of semiconductor development,” said Henry Huang, Investment Director at Micron Ventures.
ChipAgents has also bolstered its leadership team with the formation of a world-class advisory board composed of several of the semiconductor industry’s most distinguished veterans. The new board includes Wally Rhines, former CEO of Mentor Graphics (now Siemens EDA); Raúl Camposano, former CTO of Synopsys; Jack Harding, former CEO of Cadence; and Erez Tsur, former CEO of Cadence Israel. Collectively, with additional guidance from founding advisor, Dr. John Bowers, these silicon luminaries bring decades of experience in building and scaling the very companies that have defined the EDA landscape.
"ChipAgents demonstrates the major impact that AI can have on the full range of integrated circuit design tasks,” said Wally Rhines. “I’ve met with three major semiconductor companies that have done competitive assessments of AI-based design solutions, and ChipAgents is the number one choice at all three.”
"ChipAgents is pioneering a new era in semiconductor design, where AI and engineering expertise converge for smarter solutions. The implications for the semiconductor industry are nothing short of transformative, and I’m excited to support their mission,” said Raúl Camposano.
Book a demo with ChipAgents to learn more about the agentic AI EDA platform, and check out the open positions to join the pioneering team.
About ChipAgents
ChipAgents is a cutting-edge AI startup delivering generative, agentic solutions for chip design and verification. Its flagship product transforms how hardware companies define, validate, and refine RTL code, simplifying complex workflows while driving unmatched productivity and accuracy. For more information, visit ChipAgents.ai or follow us on LinkedIn and Twitter/X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251021677325/en/
Contacts
Media Contact:
press@alphadesign.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom